Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human Hs 294T cells treated with elesclomol alone or in combination with paclitaxel compared to DMSO treated

ABSTRACT: We used microarrays to detail gene expression changes in Hs 294T human melanoma cells after treatment with elesclomol alone, or in combination with paclitaxel, to aide in identifing the mechnism of action of elesclomol. Experiment Overall Design: Hs 294T human melanoma cells were grown in vitro. They were seeded at a low density and were left untreated, treated with the vehicle, treated with elesclomol, treated with paclitaxel, or treated in combination with both elesclomol and paclitaxel. They were incubated for 6 hours before harvesting.

ORGANISM(S): Homo sapiens

SUBMITTER: Kepros Jane Frances

PROVIDER: S-ECPF-GEOD-11550 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Hs 294T Cells Treated with Elesclomol Alone or in Combination with Paclitaxel Compared to DMSO Treated

2008-05-29 | GSE11550 | GEO

Transcription profiling of human 294T Cells treated with elesclomol alone or in combination with NAC compared to DMSO treated

Project description:We used microarrays to detail gene expression changes in Hs 294T human melanoma cells after treatment with elesclomol alone, or in combination with NAC, to aide in identifing the mechnism of action of elesclomol. Experiment Overall Design: Hs 294T human melanoma cells were grown in vitro. They were seeded at a low density and were left untreated, treated with the vehicle, treated with elesclomol, treated with NAC, or treated in combination with both elesclomol and NAC. The cells treated with NAC were given the NAC 30 minutes prior to additional treatments. They were incubated for 6 hours before harvesting.

| S-ECPF-GEOD-11551 | biostudies-other

Transcription profiling of human Hs 294T cells treated with elesclomol alone or in combination with paclitaxel compared to DMSO treated

Project description:We used microarrays to detail gene expression changes in Hs 294T human melanoma cells after treatment with elesclomol alone, or in combination with paclitaxel, to aide in identifing the mechnism of action of elesclomol. Experiment Overall Design: Hs 294T human melanoma cells were grown in vitro. They were seeded at a low density and were left untreated, treated with the vehicle, treated with elesclomol, treated with paclitaxel, or treated in combination with both elesclomol and paclitaxel. They were incubated for 6 hours before harvesting.

2008-06-19 | E-GEOD-11550 | biostudies-arrayexpress

Hs 294T Cells Treated with Elesclomol Alone or in Combination with NAC Compared to DMSO Treated

2008-05-29 | GSE11551 | GEO

Transcription profiling of human 294T Cells treated with elesclomol alone or in combination with NAC compared to DMSO treated

2008-06-18 | E-GEOD-11551 | biostudies-arrayexpress

Hs 294T Cells Treated with Elesclomol in Combination with Paclitaxel or NAC

Project description:This SuperSeries is composed of the SubSeries listed below.

2008-05-29 | GSE11552 | GEO

Transcription profiling by array of human U251 cells treated with DMSO or enzastaurin

Project description:We identified GSK3 as a regulator of GBM cell survival using microarray analysis, small molecule and genetic inhibitors of GSK3 activity. Various molecular and genetic approaches were then employed to dissect out the molecular mechanisms responsible for GSK3 inhibition-induced cytotoxicity. Experiment Overall Design: RNA extracted from U251 cells treated with DMSO or Enzastaurin for indicated time were hybridized to Affymetrix expression arrays (HG_U133-Plus_2) to detect changes in gene expression caused by Enzastaurin. Three replicates per sample were used.

| S-ECPF-GEOD-11285 | biostudies-other

Transcription profiling of human HMLER breast cancer cells treated with paclitaxel and salinomycin-treated HMLER breast cancer cells

Project description:Screens for agents that specifically kill epithelial cancer stem cells (CSCs) have not been possible due to the rarity of these cells within tumor cell populations and their relative instability in culture. We describe here an approach to screening for agents with epithelial CSC-specific toxicity. We implemented this method in a chemical screen and discovered compounds showing selective toxicity for breast CSCs. One compound, salinomycin, reduces the proportion of CSCs by >100-fold relative to paclitaxel, a commonly used breast cancer chemotherapeutic drug. Treatment of mice with salinomycin inhibits mammary tumor growth in vivo and induces increased epithelial differentiation of tumor cells. In addition, global gene expression analyses show that salinomycin treatment results in the loss of expression of breast CSC genes previously identified by analyses of breast tissues isolated directly from patients. This study demonstrates the ability to identify agents with specific toxicity for epithelial CSCs Experiment Overall Design: Experimentally transformed HMLER breast cancer cells were treated in culture with either paclitaxel (10nM) or salinomycin (1uM) for one week. There were three biologic replicates for each treatment condition.

| S-ECPF-GEOD-17215 | biostudies-other

Transcription profiling of human MDA-MB-435 Cells treated with 2-methoxyestradiol versus control DMSO

Project description:MDA-MB-435 breast cancer cells were treated with 2ME2 (2 µM) or vehicle alone. RNA was extracted and genomic profiling was performed using 22k Agilent microarrays. Experiment Overall Design: MDA-MB-435 breast cancer cells were treated with 2ME2 (2 µM) or vehicle alone. RNA was extracted and genomic profiling was performed using 22k Agilent microarrays.

| S-ECPF-GEOD-5665 | biostudies-other

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).

Project description:PurposeCXCR1, one of the receptors for CXCL8, has been identified as a druggable target on breast cancer cancer stem cells (CSC). Reparixin (R), an investigational oral inhibitor of CXCR1, was safely administered to metastatic breast cancer patients in combination with paclitaxel (P) and appeared to reduce CSC in a window-of-opportunity trial in operable breast cancer. The fRida trial (NCT02370238) evaluated the addition of R to weekly as first-line therapy for metastatic (m) TNBC.Subjects and methodsSubjects with untreated mTNBC were randomized 1:1 to R or placebo days 1-21 in combination with weekly P 80 mg/m2 on days 1, 8, 15 of 28-day cycles. The primary endpoint was PFS by central review.Results123 subjects were randomized (62 to R + P and 61 to placebo + P). PFS was not different between the 2 groups (median 5.5 and 5.6 months for R + P and placebo + P, respectively; HR 1.13, p = 0.5996). ALDH+ and CD24-/CD44+ CSC centrally evaluated by IHC were found in 16 and 34 of the 54 subjects who provided a metastatic tissue biopsy at study entry. Serious adverse events (21.3 and 20% of subjects) and grade ≥ 3 adverse reactions (ADR) (9.1 and 6.3% of all ADRs) occurred at similar frequency in both groups.ConclusionfRida is the first randomized, double-blind clinical trial of a CSC-targeting agent in combination with chemotherapy in breast cancer. The primary endpoint of prolonged PFS was not met.Clinical trial registration/date of registrationNCT01861054/February 24, 2015.

| S-EPMC8558154 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data